US Envoy Sergio Gor Pushes Stronger US-India Pharma Ties

US Ambassador to India Sergio Gor highlighted efforts to deepen pharmaceutical cooperation with India, emphasizing resilient supply chains. He noted the importance of fair deals for US industry leaders expanding their footprint in India. Gor also reiterated Washington's push to modernize trade policy with Central Asia, calling for repeal of the Jackson-Vanik amendment. The remarks come amid broader US-India efforts to strengthen economic ties in critical sectors.

Key Points: US Envoy Highlights Deepening Pharma Ties with India

  • US envoy highlights pharma cooperation with India
  • Focus on resilient supply chains and fair deals
  • US firms expanding footprint in India
  • Efforts to modernize trade policy with Central Asia
3 min read

US envoy Sergio Gor highlights efforts to deepen US-India pharma ties

US Ambassador Sergio Gor emphasizes resilient supply chains and fair deals for US industry, as both nations strengthen pharmaceutical cooperation.

"Stronger US-India pharma ties mean more resilient supply chains for our people. - US Ambassador Sergio Gor"

New Delhi, April 24

US Ambassador to India Sergio Gor on Friday highlighted efforts to deepen pharmaceutical cooperation with India.

Gor highlighted growing collaboration between the United States and India in the pharmaceutical sector. In a statement, he pointed to the importance of resilient supply chains and industry expansion.

"Stronger US-India pharma ties mean more resilient supply chains for our people. Great roundtable with US industry leaders today on expanding their footprint here while advocating for fair deals," he said in a post on X.

The ambassador noted that fostering a favourable business environment remains a priority, particularly for innovation-driven companies. "We're ensuring our most innovative companies lead the way in a competitive global market," he added.

The remarks come amid broader efforts by both nations to strengthen economic ties, especially in critical sectors such as healthcare, technology, and manufacturing. Increased US investment in India's pharmaceutical industry could help diversify global supply chains, reducing reliance on single-source manufacturing hubs and enhancing preparedness for future health crises.

He also reiterated Washington's push to modernise trade policy with Central Asia.

Further, separately, Gor emphasised the importance of legislative reform in unlocking trade opportunities with Central Asian nations.

In a post on X, he referred to Jim Risch, a senior US senator involved in foreign relations policy. "Always a pleasure to speak with @SenatorRisch to reaffirm our strong support for action to repeal the Jackson-Vanik amendment for key U.S. partners in Central Asia," Gor wrote.

Enacted in 1974, the Jackson-Vanik Amendment is a US trade law that denied normalised trade relations to non-market economies that restricted their citizens' right to emigrate. It was originally aimed at the Soviet Union.

Gor underscored the potential economic benefits of removing the restriction, particularly as the United States seeks to expand its footprint in emerging markets. "As I work to deepen our C5+1 cooperation, removing this outdated law can unlock the immense potential for our economic ties with Central Asian nations and boost US exports to this key region. Chairman Risch is doing a great job!" the US envoy to India added.

Risch, the Republican Senator from Idaho and Chairman of the Senate Foreign Relations Committee, in November 2025, along with a bipartisan group of lawmakers, introduced a bill to officially repeal the Jackson-Vanik restrictions for key Central Asian partners.

While the amendment was repealed over the years for post-Soviet countries like Ukraine (2006) and Russia (2012), it has technically remained on the books for several Central Asian nations (such as Kazakhstan, Tajikistan, Turkmenistan, and Uzbekistan). Because of this, these nations are forced to rely on temporary trade waivers rather than permanent normal trade relations.

The C5+1 platform, which brings together the United States and five Central Asian countries, has gained traction in recent years as Washington aims to counterbalance other global influences in the region while promoting trade, energy cooperation, and regional stability.

- ANI

Share this article:

Reader Comments

P
Priya S
Finally some sensible diplomatic work! The Jackson-Vanik amendment thing is long overdue for repeal. It's ridiculous that Central Asian nations have been stuck with temporary waivers for decades. India should also leverage this C5+1 platform for better connectivity.
M
Michael C
As someone who works in pharma supply chains, this is a win-win. India's manufacturing capability combined with American innovation can create more resilient systems. But "fair deals" for US companies shouldn't mean squeezing Indian firms. Equity matters.
S
Sneha F
Good to see bipartisan support for this. But I remain cautious - US pharma companies have a history of patent bullying. India's generic industry saved lives during COVID. Hope we don't compromise our public health flexibility for trade deals. 😷
R
Rahul R
The C5+1 angle is interesting. India has historical ties with Central Asia. If US-India cooperation includes joint initiatives there for infrastructure or pharma logistics, it could be transformative. But India should also strengthen its own regional mechanisms like the India-Central Asia dialogue.
K
Kavya N
While deepening ties is welcome, we must remember that India's domestic pharma industry employs millions. Any "fair deal" negotiation must protect Indian manufacturers from being reduced to mere contract manufacturers. We need value addition, not just volume.
J

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50